Roles
- Dodson Professor of Microbiology and Immunology
- Director of the Dodson Interdisciplinary Immunotherapy Institute
- Co-Leader of the Tumor Immunology Research Program
- Professor Emeritus
-
Biography
Dr. Gilboa, the Joe Enloe Dodson professor in the Department of Microbiology & Immunology, School of Medicine, University of Miami, USA, is known for his pioneering work in gene therapy, HIV/AIDS, and cancer immunotherapy. His group has introduced novel concepts that helped shape these fields; the use of “self-inactivating” retroviral vectors that became a common feature of retroviral and lentiviral vector, HIV TAR decoys, and mRNA transfected dendritic cell (DC) vaccines, the precursor of the COVID-19 mRNA vaccines. More recently, his lab has pioneered the use of oligonucleotide-based ligands to modulate tumor immunity, demonstrating their exceptional efficiency to target siRNAs, aptamers, and small molecule drugs, to the immune system or to tumor lesions. Dr. Gilboa’s lab has introduced new concepts in cancer immunotherapy to promote immune memory, limit immune modulation to tumors, enhance uptake of tumor antigens by dendritic cells and recently, a novel vaccination concept targeting a common set of experimentally induced neoantigens. -
Education & Training
Education
-
Honors & Awards
-
Teaching Interests
Teaching graduate students about tumor immunology and immunotherapy. -
Research Interests
The main research focus in the Gilboa lab is the development of multi-pronged approaches to cancer immunotherapy. Using novel drug and drug delivery platforms of antibody and oligonucleotide aptamer-targeted RNA therapeutics to reduce immune toxicity, his group has developed new concepts in cancer immunotherapy to promote immune memory, limit immune modulation to tumor lesions and enhance uptake of tumor antigens by dendritic cells. The current main focus is the development of a novel vaccination concept against a common set of experimentally induced neoantigens that overcomes the main limitations of targeting random mutation-generated neoantigens. Complementary projects aim at promoting the development of vaccine-induced tissue-resident memory C8+ T cells, enhancing the antitumor activity of the major cDC1 dendritic cells subset, and reinvigorating dysfunctional (exhausted) CD8+ T cells. -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.Professional Activities